H.C. Wainwright analyst Robert Burns raised the firm’s price target on Replimune Group to $17 from $12 and keeps a Buy rating on the shares. The analyst increased probability of approval for RP1 in second-line anti-PD1 failed melanoma to 75% from 65% following the primary analysis of the IGNYTE trial.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REPL:
- Replimune Group’s IGNYTE Trial Shows Promising Melanoma Outcomes
- Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
- Replimune Group presents positive data from RP1 and RP2 programs at ASCO
- Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update